Currently, one would expect that improved results with a higher percentage of MRA treatment and doses can be expected, because SGLT2 inhibitors reduce the risk of MRA-associated hyperkaliemia [26], and novel potassium binders like patiromer and sodium zirconium cyclosilicate are now available [27,28] and are recommended in the ESC 2021 HF guidelines [6]. Here, SLC5A2 is linked to hydrops fetalis.